Febrile UTI is a common cause of hospital admission and can lead to serious illness, particularly in older adults and people with catheters. Many patients experience relapses, often requiring new courses of antibiotics and increasing the risk of antibiotic resistance.
The HIPSTER trial investigates whether methenamine hippurate (Hiprex), a urinary antiseptic, can reduce the risk of new febrile UTI episodes after completed antibiotic treatment.
HIPSTER is an international clinical trial investigating whether methenamine hippurate (Hiprex) can reduce the risk of recurrent febrile urinary tract infection (UTI) after hospital care.
The HIPSTER study is an international, multicentre clinical trial involving participants from multiple centres and countries. Participating sites collaborate throughout the study to support recruitment, follow-up, and collection of clinical data.
The following sites in Sweden are currently participating in the study. Additional sites will be added as they are confirmed.
An international clinical trial investigating whether methenamine hippurate can prevent recurrent febrile UTI after hospital care.
Febrile UTI is a common cause of hospital admission and can lead to serious illness, particularly in older adults and people with catheters. Many patients experience relapses, often requiring new courses of antibiotics and increasing the risk of antibiotic resistance.
Methenamine hippurate (Hiprex) is a urinary antiseptic. The HIPSTER trial investigates whether it can reduce the risk of new febrile UTI episodes after completed antibiotic treatment.
Patients treated in hospital for a febrile UTI are recruited at discharge and randomly assigned to methenamine hippurate or placebo, which is taken during the first 12 months. Outcomes and safety are monitored through telephone follow-ups and review of medical records.
Participants are followed for 18 months.
No. Participants are recruited at hospital discharge after treatment for a febrile UTI and must meet the study’s eligibility criteria. The study team at the participating hospital assesses whether a patient can take part.
Yes, placebo is used under careful monitoring and is necessary to reliably determine whether the treatment has an effect.
Outcomes and safety are monitored throughout the study through telephone follow-ups and review of medical records.
Personal data is handled in accordance with the General Data Protection Regulation (GDPR). You can read more in our privacy policy or contact the study team.
Results will be published once the study has been completed and the data analysed. Updates will be posted in the news section.
You can read the latest news or get in touch with the study team via our contact page.
